Int J Cardiol:CHA2DS2-VASc评分与ACS患者冠状动脉疾病的严重程度、残余血小板反应性和长期临床结局的关系!

2018-03-21 xing.T MedSci原创

在ACS患者的队列中,CHA2DS2-VASc评分与冠状动脉疾病的严重程度和残余血小板反应性相关,因此,它可预测不良事件的长期风险。

CHA2DS2-VASc评分可预测房颤患者卒中风险,但最近有报道其在ACS患者中具有预后作用。近日,心血管领域权威杂志International Journal of Cardiology上发表了一篇研究文章,研究人员试图评估CHA2DS2-VASc评分预测冠状动脉病变严重程度、高残留血小板反应性和急性冠状动脉综合征(ACS)患者长期结局的能力。

总的来说,该研究纳入了1729名连续就诊的接受侵入性治疗的ACS患者。研究人员通过氯吡格雷负荷后的透光率集合度测定评估了血小板反应性。根据CHA2DS2-VASc评分患者被分为:A组 = 0、B = 1、C = 2、D = 3、E = 4和F ≥ 5。

CHA2DS2-VASc评分较高的患者更有可能发生冠状动脉多支病变(对于A、B、C、D、E和F组分别为37%、47%、55%、62%、67和75%;P < 0.001);此外,CHA2DS2-VASc评分与残余血小板反应性呈线性相关(r = 0.77;P<0.001)。在长期随访过程中,A、B、C、D、E和F组估计的不良事件(MACCE:心源性死亡、米河、卒中或任何紧急冠状动脉血运重建)发生率分别为3%、8%、10%、14%、19%和24%,P<0.001。多变量分析显示CHA2DS2-VASc评分是冠状动脉病变严重程度、高残留血小板反应性和MACCE的独立预测因子。

在ACS患者的队列中,CHA2DS2-VASc评分与冠状动脉疾病的严重程度和残余血小板反应性相关,因此,它可预测不良事件的长期风险。

原始出处:


Fernando Scudiero,et al. Relationship between CHA2DS2-VASc score, coronary artery disease severity, residual platelet reactivity and long-term clinical outcomes in patients with acute coronary syndrome.International Journal of Cardiology.2018. https://doi.org/10.1016/j.ijcard.2018.03.086

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2022810, encodeId=a6c02022810c0, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Mon Jan 07 02:26:00 CST 2019, time=2019-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938819, encodeId=80941938819b1, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Aug 06 16:26:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843160, encodeId=7949184316082, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Mon Aug 27 21:26:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781893, encodeId=fbb51e81893a4, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Aug 30 20:26:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021198, encodeId=14142021198f6, content=<a href='/topic/show?id=0143456eae' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4567, encryptionId=0143456eae, topicName=CHA2DS2-VASc评分)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Fri Sep 21 11:26:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028484, encodeId=10b1202848477, content=<a href='/topic/show?id=f81d89026de' target=_blank style='color:#2F92EE;'>#血小板反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89026, encryptionId=f81d89026de, topicName=血小板反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Thu Aug 30 10:26:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782918, encodeId=b07f1e8291854, content=<a href='/topic/show?id=c1fa456550' target=_blank style='color:#2F92EE;'>#CHA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4565, encryptionId=c1fa456550, topicName=CHA2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Tue Oct 16 14:26:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252912, encodeId=393312529125a, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279249, encodeId=008612e92491e, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573494, encodeId=89ab15e34949d, content=<a href='/topic/show?id=79b34566e1' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4566, encryptionId=79b34566e1, topicName=CHA2DS2-VASc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2615885776, createdName=canlab, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2022810, encodeId=a6c02022810c0, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Mon Jan 07 02:26:00 CST 2019, time=2019-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938819, encodeId=80941938819b1, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Aug 06 16:26:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843160, encodeId=7949184316082, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Mon Aug 27 21:26:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781893, encodeId=fbb51e81893a4, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Aug 30 20:26:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021198, encodeId=14142021198f6, content=<a href='/topic/show?id=0143456eae' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4567, encryptionId=0143456eae, topicName=CHA2DS2-VASc评分)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Fri Sep 21 11:26:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028484, encodeId=10b1202848477, content=<a href='/topic/show?id=f81d89026de' target=_blank style='color:#2F92EE;'>#血小板反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89026, encryptionId=f81d89026de, topicName=血小板反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Thu Aug 30 10:26:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782918, encodeId=b07f1e8291854, content=<a href='/topic/show?id=c1fa456550' target=_blank style='color:#2F92EE;'>#CHA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4565, encryptionId=c1fa456550, topicName=CHA2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Tue Oct 16 14:26:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252912, encodeId=393312529125a, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279249, encodeId=008612e92491e, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573494, encodeId=89ab15e34949d, content=<a href='/topic/show?id=79b34566e1' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4566, encryptionId=79b34566e1, topicName=CHA2DS2-VASc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2615885776, createdName=canlab, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=)]
    2018-08-06 quxin068
  3. [GetPortalCommentsPageByObjectIdResponse(id=2022810, encodeId=a6c02022810c0, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Mon Jan 07 02:26:00 CST 2019, time=2019-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938819, encodeId=80941938819b1, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Aug 06 16:26:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843160, encodeId=7949184316082, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Mon Aug 27 21:26:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781893, encodeId=fbb51e81893a4, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Aug 30 20:26:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021198, encodeId=14142021198f6, content=<a href='/topic/show?id=0143456eae' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4567, encryptionId=0143456eae, topicName=CHA2DS2-VASc评分)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Fri Sep 21 11:26:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028484, encodeId=10b1202848477, content=<a href='/topic/show?id=f81d89026de' target=_blank style='color:#2F92EE;'>#血小板反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89026, encryptionId=f81d89026de, topicName=血小板反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Thu Aug 30 10:26:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782918, encodeId=b07f1e8291854, content=<a href='/topic/show?id=c1fa456550' target=_blank style='color:#2F92EE;'>#CHA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4565, encryptionId=c1fa456550, topicName=CHA2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Tue Oct 16 14:26:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252912, encodeId=393312529125a, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279249, encodeId=008612e92491e, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573494, encodeId=89ab15e34949d, content=<a href='/topic/show?id=79b34566e1' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4566, encryptionId=79b34566e1, topicName=CHA2DS2-VASc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2615885776, createdName=canlab, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2022810, encodeId=a6c02022810c0, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Mon Jan 07 02:26:00 CST 2019, time=2019-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938819, encodeId=80941938819b1, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Aug 06 16:26:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843160, encodeId=7949184316082, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Mon Aug 27 21:26:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781893, encodeId=fbb51e81893a4, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Aug 30 20:26:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021198, encodeId=14142021198f6, content=<a href='/topic/show?id=0143456eae' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4567, encryptionId=0143456eae, topicName=CHA2DS2-VASc评分)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Fri Sep 21 11:26:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028484, encodeId=10b1202848477, content=<a href='/topic/show?id=f81d89026de' target=_blank style='color:#2F92EE;'>#血小板反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89026, encryptionId=f81d89026de, topicName=血小板反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Thu Aug 30 10:26:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782918, encodeId=b07f1e8291854, content=<a href='/topic/show?id=c1fa456550' target=_blank style='color:#2F92EE;'>#CHA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4565, encryptionId=c1fa456550, topicName=CHA2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Tue Oct 16 14:26:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252912, encodeId=393312529125a, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279249, encodeId=008612e92491e, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573494, encodeId=89ab15e34949d, content=<a href='/topic/show?id=79b34566e1' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4566, encryptionId=79b34566e1, topicName=CHA2DS2-VASc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2615885776, createdName=canlab, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2022810, encodeId=a6c02022810c0, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Mon Jan 07 02:26:00 CST 2019, time=2019-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938819, encodeId=80941938819b1, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Aug 06 16:26:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843160, encodeId=7949184316082, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Mon Aug 27 21:26:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781893, encodeId=fbb51e81893a4, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Aug 30 20:26:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021198, encodeId=14142021198f6, content=<a href='/topic/show?id=0143456eae' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4567, encryptionId=0143456eae, topicName=CHA2DS2-VASc评分)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Fri Sep 21 11:26:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028484, encodeId=10b1202848477, content=<a href='/topic/show?id=f81d89026de' target=_blank style='color:#2F92EE;'>#血小板反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89026, encryptionId=f81d89026de, topicName=血小板反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Thu Aug 30 10:26:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782918, encodeId=b07f1e8291854, content=<a href='/topic/show?id=c1fa456550' target=_blank style='color:#2F92EE;'>#CHA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4565, encryptionId=c1fa456550, topicName=CHA2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Tue Oct 16 14:26:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252912, encodeId=393312529125a, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279249, encodeId=008612e92491e, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573494, encodeId=89ab15e34949d, content=<a href='/topic/show?id=79b34566e1' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4566, encryptionId=79b34566e1, topicName=CHA2DS2-VASc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2615885776, createdName=canlab, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2022810, encodeId=a6c02022810c0, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Mon Jan 07 02:26:00 CST 2019, time=2019-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938819, encodeId=80941938819b1, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Aug 06 16:26:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843160, encodeId=7949184316082, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Mon Aug 27 21:26:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781893, encodeId=fbb51e81893a4, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Aug 30 20:26:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021198, encodeId=14142021198f6, content=<a href='/topic/show?id=0143456eae' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4567, encryptionId=0143456eae, topicName=CHA2DS2-VASc评分)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Fri Sep 21 11:26:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028484, encodeId=10b1202848477, content=<a href='/topic/show?id=f81d89026de' target=_blank style='color:#2F92EE;'>#血小板反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89026, encryptionId=f81d89026de, topicName=血小板反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Thu Aug 30 10:26:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782918, encodeId=b07f1e8291854, content=<a href='/topic/show?id=c1fa456550' target=_blank style='color:#2F92EE;'>#CHA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4565, encryptionId=c1fa456550, topicName=CHA2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Tue Oct 16 14:26:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252912, encodeId=393312529125a, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279249, encodeId=008612e92491e, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573494, encodeId=89ab15e34949d, content=<a href='/topic/show?id=79b34566e1' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4566, encryptionId=79b34566e1, topicName=CHA2DS2-VASc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2615885776, createdName=canlab, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2022810, encodeId=a6c02022810c0, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Mon Jan 07 02:26:00 CST 2019, time=2019-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938819, encodeId=80941938819b1, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Aug 06 16:26:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843160, encodeId=7949184316082, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Mon Aug 27 21:26:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781893, encodeId=fbb51e81893a4, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Aug 30 20:26:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021198, encodeId=14142021198f6, content=<a href='/topic/show?id=0143456eae' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4567, encryptionId=0143456eae, topicName=CHA2DS2-VASc评分)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Fri Sep 21 11:26:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028484, encodeId=10b1202848477, content=<a href='/topic/show?id=f81d89026de' target=_blank style='color:#2F92EE;'>#血小板反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89026, encryptionId=f81d89026de, topicName=血小板反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Thu Aug 30 10:26:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782918, encodeId=b07f1e8291854, content=<a href='/topic/show?id=c1fa456550' target=_blank style='color:#2F92EE;'>#CHA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4565, encryptionId=c1fa456550, topicName=CHA2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Tue Oct 16 14:26:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252912, encodeId=393312529125a, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279249, encodeId=008612e92491e, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573494, encodeId=89ab15e34949d, content=<a href='/topic/show?id=79b34566e1' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4566, encryptionId=79b34566e1, topicName=CHA2DS2-VASc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2615885776, createdName=canlab, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=)]
    2018-10-16 huperzia
  8. [GetPortalCommentsPageByObjectIdResponse(id=2022810, encodeId=a6c02022810c0, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Mon Jan 07 02:26:00 CST 2019, time=2019-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938819, encodeId=80941938819b1, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Aug 06 16:26:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843160, encodeId=7949184316082, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Mon Aug 27 21:26:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781893, encodeId=fbb51e81893a4, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Aug 30 20:26:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021198, encodeId=14142021198f6, content=<a href='/topic/show?id=0143456eae' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4567, encryptionId=0143456eae, topicName=CHA2DS2-VASc评分)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Fri Sep 21 11:26:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028484, encodeId=10b1202848477, content=<a href='/topic/show?id=f81d89026de' target=_blank style='color:#2F92EE;'>#血小板反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89026, encryptionId=f81d89026de, topicName=血小板反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Thu Aug 30 10:26:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782918, encodeId=b07f1e8291854, content=<a href='/topic/show?id=c1fa456550' target=_blank style='color:#2F92EE;'>#CHA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4565, encryptionId=c1fa456550, topicName=CHA2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Tue Oct 16 14:26:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252912, encodeId=393312529125a, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279249, encodeId=008612e92491e, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573494, encodeId=89ab15e34949d, content=<a href='/topic/show?id=79b34566e1' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4566, encryptionId=79b34566e1, topicName=CHA2DS2-VASc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2615885776, createdName=canlab, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=2022810, encodeId=a6c02022810c0, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Mon Jan 07 02:26:00 CST 2019, time=2019-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938819, encodeId=80941938819b1, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Aug 06 16:26:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843160, encodeId=7949184316082, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Mon Aug 27 21:26:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781893, encodeId=fbb51e81893a4, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Aug 30 20:26:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021198, encodeId=14142021198f6, content=<a href='/topic/show?id=0143456eae' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4567, encryptionId=0143456eae, topicName=CHA2DS2-VASc评分)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Fri Sep 21 11:26:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028484, encodeId=10b1202848477, content=<a href='/topic/show?id=f81d89026de' target=_blank style='color:#2F92EE;'>#血小板反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89026, encryptionId=f81d89026de, topicName=血小板反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Thu Aug 30 10:26:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782918, encodeId=b07f1e8291854, content=<a href='/topic/show?id=c1fa456550' target=_blank style='color:#2F92EE;'>#CHA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4565, encryptionId=c1fa456550, topicName=CHA2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Tue Oct 16 14:26:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252912, encodeId=393312529125a, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279249, encodeId=008612e92491e, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573494, encodeId=89ab15e34949d, content=<a href='/topic/show?id=79b34566e1' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4566, encryptionId=79b34566e1, topicName=CHA2DS2-VASc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2615885776, createdName=canlab, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=)]
    2018-03-23 yaanren
  10. [GetPortalCommentsPageByObjectIdResponse(id=2022810, encodeId=a6c02022810c0, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Mon Jan 07 02:26:00 CST 2019, time=2019-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938819, encodeId=80941938819b1, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Aug 06 16:26:00 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843160, encodeId=7949184316082, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Mon Aug 27 21:26:00 CST 2018, time=2018-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781893, encodeId=fbb51e81893a4, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Aug 30 20:26:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021198, encodeId=14142021198f6, content=<a href='/topic/show?id=0143456eae' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4567, encryptionId=0143456eae, topicName=CHA2DS2-VASc评分)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d0b2500136, createdName=12498b08m90暂无昵称, createdTime=Fri Sep 21 11:26:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028484, encodeId=10b1202848477, content=<a href='/topic/show?id=f81d89026de' target=_blank style='color:#2F92EE;'>#血小板反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89026, encryptionId=f81d89026de, topicName=血小板反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Thu Aug 30 10:26:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782918, encodeId=b07f1e8291854, content=<a href='/topic/show?id=c1fa456550' target=_blank style='color:#2F92EE;'>#CHA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4565, encryptionId=c1fa456550, topicName=CHA2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Tue Oct 16 14:26:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252912, encodeId=393312529125a, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279249, encodeId=008612e92491e, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573494, encodeId=89ab15e34949d, content=<a href='/topic/show?id=79b34566e1' target=_blank style='color:#2F92EE;'>#CHA2DS2-VASc#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4566, encryptionId=79b34566e1, topicName=CHA2DS2-VASc)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2615885776, createdName=canlab, createdTime=Fri Mar 23 09:26:00 CST 2018, time=2018-03-23, status=1, ipAttribution=)]

相关资讯

SCI REP:CHADS2和CHA2DS2-VASc评分对房颤患者急性心肌梗死的预测价值!

由此可见,CHA2DS2-VASc评分具有很好的识别高危房颤患者的预测价值,但是在预测发生急性心肌梗死的患者上其并不显著优于CHADS2评分。

Ann Med:荟萃分析显示CHADS2和CHA2DS2-VASc评分对非房颤患者卒中发生的诊断性良好

目的:CHA2DS2-VASc是伯明翰2009开发的CHADS2评分的延伸。在临床上当考虑房颤患者卒中发生额外的风险时,用此评分进行风险分层。然而,它在非房颤的人口中的作用是尚不清楚。本研究的目的是评估CHADS2 和CHA2DS2-VASc评分系统的准确性。方法:纳入CHADS2和CHA2DS2-VASc评分对非房颤患者卒中发生的风险分层的研究。结果: 在选出的114项研究中,最终选择了六个试验

Stroke:亚洲房颤患者用CHA2DS2-VASc评分进行卒中危险分层性能如何?

由此可见,亚洲人中CHA2DS2-VASc评分的性能与西方人群相当。该评分在定义真正的卒中/血栓栓塞低风险AF患者上表现出了良好的性能。

Int J Cardiol:入院前CHA2DS2-VASc评分与急性心脑血管事件患者预后有何关系?

由此可见,急性脑血管事件的患者入院时较高的CHA2DS2-VASc评分与较高的死亡率和出院时严重残疾相关。

周玉杰:2012ESC心房颤动管理指南

2010ESC心房颤动治疗指南发布已经2年了,2年多来一些新型口服抗凝药物的临床研究如AVERROES(Apixaban vs ASA)、ROCKET-AF(Rivaroxaban vs VKA ) 、 ARISTOTLE (Apixaban ) 相继发表,为新型抗凝药物临床应用提供了更充分的证据,同时一些新的治疗药物被批准上市,鉴于此2012年8月27日ESC会议发布房颤治疗指南2012更新版,

Europace:成功的导管消融可减少CHA2DS2-VASc评分≥1分房颤患者的心血管事件发生

房颤是临床常见的心律失常,是脑卒中发生的独立预测因子。近年来导管消融被认为是有症状者或药物治疗无效的房颤患者的有效治疗手段,然而目前大多数临床研究的随访时间均较短,且入选的患者多属低危,因此目前对于房颤患者成功导管消融能否改善患者的长期预后还不清楚。 目前的理论认为无症状的房颤患者较使用抗心律失常药物的患者具有更好的临床预后,因此我们认为导管消融后无房性心律失常发作可显着改善患者的临床症状,因此